Sandra J Burke

age ~77

from Momence, IL

Get Report

Also known as:

Sandra L Burke
Sandra H Burke

Phone and address:: 3201 N 16840E Rd, Momence, IL 60954
(815)4729809

Connected to:

Sandra Burke Phones & Addresses

3201 N 16840E Rd, Momence, IL 60954 • (815)4729809
Bradley, IL
Bourbonnais, IL
Homewood, IL
Orland Hills, IL

Work

Company:

Securitas security services usa, inc
Mar 2005
Position:

Sergeant, supervisor

Education

School / High School:

CENTRAL YMCA HIGH SCHOOL- Chicago, IL
Nov 1977
Specialities:

High School Diploma

Skills

Windows Vista and Internet

Real Estate Brokers

Sandra Burke, New York Agent

view source

Work:

City Solutions Real Estate
(646)8415160 (Phone)
License #10401238224

License Records

Sandra L Burke

License #:

1965582 - Expired

Category:

Health Care

Issued Date:

Oct 10, 1988

Effective Date:

Aug 30, 2000

Expiration Date:

Jul 31, 1998

Type:

Registered Nurse

Name / Title

Company / Classification

Phones & Addresses

Sandra M Burke
Secretary,Treasurer

SOUND FISH, INC

Isbn (Books And Publications)

Fashion Artist: Drawing Techniques to Portfolio Presentation

view source

Author
Sandra Burke

ISBN #
0473054388

Fashion Computing: Design Techniques and CAD

view source

Author
Sandra Burke

ISBN #
0958239134

Fashion Artist

view source

Author
Sandra Burke

ISBN #
0958239177

Trails of Twig-Prints

view source

Author
Sandra A. Burke

ISBN #
0805917845

Resumes

Sandra Burke Chicago, IL

view source

Work:

Securitas Security Services USA, inc

Mar 2005 to Apr 2010
Sergeant, Supervisor Digby Security

Sep 2001 to Feb 2005
Sergeant, Supervisor

Education:

CENTRAL YMCA HIGH SCHOOL
Chicago, IL
Nov 1977
High School Diploma

Skills:

Windows Vista and Internet

Lawyers & Attorneys

Sandra Burke - Lawyer

view source

Specialties:

Securities
Corporate Law

ISLN:

900596542

Admitted:

1991

University:

Santa Clara University, B.A., 1978

Law School:

Santa Clara University, J.D., 1991

Sandra Burke - Lawyer

view source

ISLN:

917646537

Sandra Burke - Lawyer

view source

Office:

Dawe & Burke

ISLN:

908665745

Admitted:

1989

University:

Memorial University of Newfoundland, 1985

Law School:

Dalhousie Law School, LL.B., 1988

Us Patents

Systems And Methods For Delivering A Rapamycin Analog That Do Not Inhibit Human Coronary Artery Endothelial Cell Migration
view source
US Patent:

20080003254, Jan 3, 2008
Filed:

May 22, 2007
Appl. No.:

11/752079
Inventors:

Matthew Mack - Chicago IL, US
Sandra Burke - Libertyville IL, US
John Toner - Libertyville IL, US
Keith Cromack - Gurnee IL, US
Assignee:

ABBOTT LABORATORIES - Abbott Park IL
International Classification:

A61F 2/06
A61K 31/4353
A61P 41/00
A61P 9/00
US Classification:

424423000, 514291000
Abstract:

A drug-eluting endoprosthesis is configured for inhibiting restenosis and thrombosis, and for promoting healing of a lesion in a body of a subject. Such an endoprosthesis includes at least a supporting structure and a therapeutically effective amount of the rapamycin analog is disposed thereon. The therapeutically effective amount of the rapamycin analog allows for the rapamycin analog to elute from the supporting structure so as to obtain a concentration of the rapamycin analog that is sufficient for inhibiting restenosis and/or inhibiting thrombosis. Also, the therapeutically effective amount of rapamycin analog is substantially devoid of inhibiting cell migration such that migrating cells promote healing of the lesion.

Compositions And Methods For Administering Dexamethasone Which Promote Human Coronary Artery Endothelial Cell Migration
view source
US Patent:

20080004694, Jan 3, 2008
Filed:

May 22, 2007
Appl. No.:

11/752093
Inventors:

Matthew Mack - Chicago IL, US
Sandra Burke - Libertyville IL, US
John Toner - Libertyville IL, US
Keith Cromack - Gurnee IL, US
Assignee:

ABBOTT LABORATORIES - Abbott Park IL
International Classification:

A61F 2/06
US Classification:

623001420
Abstract:

A drug-eluting endoprosthesis is configured for inhibiting restenosis and thrombosis, and for promoting healing of a lesion in a body of a subject. Such an endoprosthesis includes at least a supporting structure and a therapeutically effective amount of dexamethasone is disposed thereon. The therapeutically effective amount of dexamethasone allows for the drug to elute from the supporting structure so as to obtain a concentration of dexamethasone that is sufficient for inhibiting restenosis and/or inhibiting thrombosis. Also, the therapeutically effective amount of dexamethasone is substantially devoid of inhibiting cell migration such that migrating cells promote healing of the lesion. Additionally, the therapeutically effective amount of dexamethasone induces cell migration such that migrating cells promote healing of the lesion.